Garwood Medical Devices is developing two therapeutic electrode-powered products based on licences from University of Buffalo, having last raised $3.6m in 2016.

Garwood Medical Devices, a US-based therapeutic electrode device developer based on University of Buffalo research, is seeking $3m for its series B round, the university revealed yesterday. None of the round’s potential participants have been named and it is unclear whether Garwood has already secured capital. Founded in 2014, Garwood Medical Devices is developing two electrode-centred medical devices that help promote wound healing and prevent infection in metal orthopaedic implants such as prosthetic joints. Garwood’s first product, the Biofilm Disruption Device (BDD), tackles implant infections by delivering a low-voltage current that prompts a chemical reaction on the implant’s surface to kill and repel bacteria. The technology consists of a low-voltage power source, two electrode skin patches and a small needle inserted into the body to transfer a charge to the prosthesis. BDD was conceived in the lab of Mark Ehrensberger, an assistant professor in the Department of Biomedical Engineering, which is jointly affiliated to University of Buffalo’s School of Engineering and Applied Sciences and its Jacobs School of Medicine and Biomedical Sciences. Garwood is also commercialising an electronic wound bandage dubbed EnerAid that emits power and magnetic pulses to promote local blood flow and thus wound healing.  The bandage connects to the internet to give doctors live information on the patient’s condition. EnerAid is the result of collaborative work between Garwood Medical and Albert Titus, professor and chairman of the Department of Biomedical Engineering. Funds from the planned series B round will go towards trials of the BDD device in preparation for a submission to US regulator Food and Drug Administration in 2020.  The proceeds will also support the continued development of EnerAid. Garwood Medical Devices last raised funding in a $3.6m series A round in 2016 backed by unnamed private investors from Buffalo’s business and medical communities. – Feature image courtesy of Douglas Levere / University at Buffalo.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?